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Condensation 
 
Recurrent urinary tract infections are associated with sexual dysfunction, this is improved 
following treatment with intravestical Hyaluronic Acid with a sustained effect for 12 months.  
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Abstract  
 
The effect of intravesical instillations with Hyaluronic Acid on sexual dysfunction in women 
with recurrent urinary tract infections (RUTI). 
Nightingale G, Shehab Q, Kandiah C, Rush L, Rowe-Jones C, Phillips CH. 
 
Objective: 
To determine whether sexual dysfunction in women with recurrent urinary tract infections 
(RUTI) improved following treatment with intravesical Hyaluronic Acid (HA) instillations.  
 
Study Design: 
Ethical approval was obtained for a prospective study to be performed. Patients referred for 
bladder instillations to treat RUTI, and who were sexually active, were recruited to the study. 
A selection of validated questionnaires (ICIQ-UI, ICIQ-VS, FSDS-R, ICIQ-FLUTS, 
O’Leary/Sant and PGI-I) were completed at baseline, three, six and 12 months after initiation 
of treatment with bladder instillations. Treatment consisted of weekly bladder instillations 
with a preparation containing HA for four weeks then monthly for two further treatments. 
Results were populated in SPSS for statistical analysis and statistical significance was 
powered for 22 patients. 
 
Results: 
Thirty women were included in the study. FSDS-R was used to determine sexual dysfunction 
and showed that 57% patients with RUTI had significant sexual distress. There was a 
significant improvement in FSDS-R at three, six and 12 months when compared to baseline 
(Friedman two-way analysis p<0.001). ICIQ FLUTS F and I scores, O’Leary/Sant, ICIQ VS 
and PGI-I also showed a statistically significant improvement throughout the period of follow 
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up. A statistically significant, negative correlation was found between FSDS-R and PGI-I at 
12 months (r= -0.468, p=0.009). 
 
Conclusion:  
 
We have reinforced previous work showing the association between RUTI and sexual 
dysfunction, and an improvement in bladder symptoms following treatment with HA.   To 
our knowledge, this is the first study to prove an improvement in sexual dysfunction 
following intravesical treatment with HA which is sustained for up to 12 months. 
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Introduction: 
 
Recurrent urinary tract infections (RUTI) in women are common, with recurrence occurring 
within 3-6 months in 25-35% following an initial infection.1 RUTI can be debilitating and 
have a profound effect on a woman’s quality of life. Although not commonly explored in 
patient consultations, sexual dysfunction is reported in as many as 46% women with lower 
urinary tract symptoms. Salonia et al also showed that 60% of women with sexual arousal 
disorders and 61% of women with sexual pain disorders complained of RUTI.2 Likewise, 
60% women with RUTI are prone to suffer from secondary provoked vestibulodynia.3 
 
It is believed that a deficiency of the uroepithelial glycosaminoglycan (GAG) layer of the 
bladder facilitates bacterial adherence, leading to recurrent infection.4 Treatment to replenish 
this protective uroepithelium with intravesical instillation of the glucosamine Hyaluronic 
Acid (HA) has been proven to reduce the incidence of RUTI.1, 5-7 
 
Sexual dysfunction associated with RUTI is likely to have many correlations with sexual 
dysfunction and painful bladder syndrome (PBS). In both conditions, the changes in the 
uroepithelium following HA treatment make women less likely to develop an infection and 
experience pain, even after intercourse, and consequently the cycle of negative association is 
broken. Hung et al showed an improvement in sexual dysfunction when associated with PBS 
following HA treatment in their multicentre study.8 We hypothesise a similar effect would be 
seen when HA is used to treat RUTI. This study is designed to determine the number of 
patients with RUTI who see an improvement in their sexual dysfunction score following a 
course of intravesical treatment. 
 
 
Materials and Methods: 
 
Ethical approval was obtained for this prospective study (approved by the NRES South 
Central – Oxford A Research Ethics Committee, reference 14/SC/0112). It was calculated 
that 22 patients were needed to show statistical significance. This calculation was based on a 
background incidence of sexual dysfunction in 30% women, increasing to 60% in those with 
recurrent urinary tract infections.2,9,10. We assumed an improvement in 50% patients 
following treatment. 
 
Patients referred for intravesical Hyaluronic Acid instillations to treat either bacterial or 
abacterial RUTI were approached about the study. All women had been seen by a Consultant 
Gynaecologist in the outpatient department and deemed suitable for the study. Inclusion 
criteria were sexually active women requiring intravesical treatment for RUTI. Any other 
major contributor for sexual dysfunction (eg. endometriosis, pelvic pain, pelvic inflammatory 
disease) were exclusions. Further demographic data was not collected for this study as 
patients acted as their own controls.  Women were counselled about the study and written 
consent was obtained. 
 
A series of validated questionnaires including ICIQ-FLUTS, ICIQ-VS, O’Leary/Sant, ICIQ-
UI short form and FSDS-R were completed prior to treatment. Treatment consisted of either 
iAluRil® (Hyaluronic acid and sodium chondroitin sulphate, Aspire Pharma Ltd, Petersfield, 
UK) or Cystistat® (Sodium hyaluronate, Teva UK Ltd, West Yorkshire, UK) instillations 
performed weekly for four weeks and then monthly for a further two treatments.  
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The same battery of questionnaires were then completed at three months and six months, as 
well as a Patient Global Impression of Improvement (PGI-I) score. Patients were either 
reviewed in clinic or contacted by letter and asked to complete and return the validated 
questionnaires and PGI-I again at 12 months. Any women who did not complete the intended 
course of treatment and those who were no longer sexually active at follow up were 
excluded. Answers on ICIQ VS Sexual Matters Score was used to confirm sexual activity. 
Results were populated in SPSS Statistics 2012 (SPSS Inc. an IBM Company, Chicago, 
USA) for analysis. Correlations were calculated using Pearson’s correlation coefficient and 
baseline scores were compared to follow up scores using Friedman’s two-way analysis of 
variance by ranks. 
 
Results: 
 
Thirty patients were included for analysis. The mean age of patients was 39 years (SD 13.32). 
Thirteen patients received treatment with Cystistat® and 17 received iAluRil®. 
 
Median scores were calculated for each validated questionnaire and the probability of change 
over the course of treatment was calculated using Friedman non parametric paired valuables. 
Full results are shown below in Table I. 
 
Using FSDS-R scores as an assessment of sexual dysfunction (possible score range 0 to 52), 
we found that at baseline the median score in our population was 17 (IR 27.25). There was a 
significant fall in this score at all points of follow up although the median score at 6 months 
was higher than 3 months. When asked at 12 months, the median score had dropped to 1.74 
(IR 19.41). This is shown in Graph I along with the change in ICIQ-VS Sexual Matters score. 
 
Analysing the data for individual patients showed a similar pattern; eight patients (27%) 
reported an FSDS-R score of zero at baseline, indicating the absence of any sexual distress. 
The score for these patients did not change throughout follow up. Of the remaining patients, 
73% (16/22) had some reduction in their FSDS-R score at 6 months. 12 month follow up data 
was available for 13 of these patients and 61% of them had a reduction in their FSDS-R score 
compared to baseline.  
 
Using an FSDS-R score ≥11 to discriminate between women with and those without severe 
sexual distress11, 57% had sexual distress at baseline. Although not powered for significance, 
looking at these 17 patients, the change in FSDS-R scores was markedly different from 
baseline to 12 months. The median score in this group fell from 31.47 to 15.21 at baseline 
and 12 months respectively. 
 
The mean PGI-I score showed a gradual improvement in patients’ global impression of 
symptoms over the period of follow up. The improvement in PGI-I with time was statistically 
significant between three months and 12 months (p=0.001). 
 
Pearson’s correlations were performed on all our variables. A statistically significant negative 
correlation was found between FSDS-R and PGI-I at 12 months (r= -0.468, p=0.009). This 
suggests that a positive impact on sexual dysfunction following treatment plays a part in 
women feeling better overall. This was reinforced by a strong positive correlation seen 
between the effect on quality of life score in the ICIQ-VS questionnaire and FSDS-R at 12 
months (r=0.748, p<0.001). 
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There was a strong positive correlation between ICIQ VS Sexual Matters score and FSDS-R 
(r=0.833, p<0.001) with an associated negative correlation to PGI-I score (r= -0.521, 
p=0.003). Although the change in ICIQ VS Sexual Matters score was not significantly 
lowered throughout the period of follow up, the correlation between a lower Sexual Matters 
score and improved PGI-I is statistically significant. A negative correlation was found 
between age and PGI-I (r= -0.415, p=0.025).  
 
There was a negative correlation noted between PGI-I and O’Leary/Sant problem and 
symptoms scores (r= -0.569, p=0.001 and r= -0.473, p=0.008 respectively) at 12 months 
following treatment. The link between lower urinary tract symptoms and sexual dysfunction 
was shown in a moderate positive correlation between FSDS-R and O’Leary/Sant problem 
score (r=0.408, p=0.025).  
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Comments: 
 
This study reinforces previous work showing a positive correlation between sexual 
dysfunction and lower urinary tract symptoms, defined by the FSDS-R and O’Leary/Sant 
problem score respectively.2 Over half of our study population had significant sexual distress 
(defined as an FSDS-R score ≥11)11 at baseline and we present clear evidence that treatment 
for RUTI with intravesical HA significantly improves both urinary symptoms and associated 
sexual dysfunction. Twenty seven per cent of patients did not report any associated sexual 
dysfuntion. 
 
Almost three quarters of patients with sexual dysfunction at baseline found some 
improvement, however slight, at six months following treatment. The reason for this 
improvement is not completely understood but there are several schools of thought. It has 
been shown that pelvic pain is reduced following HA instillations when used for painful 
bladder syndrome.7 Any pain experienced in consequence to recurrent infection would also 
be improved, which in turn could impact on sexual function.  
 
Given that the full course of HA instillations lasted only 6 weeks, the sustained improvement 
in symptoms until the end of our study period, one year from the start of treatment, suggests 
there may be more than a physical effect on the GAG layer involved. It is possible that the 
deficiencies within the GAG layer are replenished and the cycle of recurrent infection is 
broken. Conversely, it may be the psychological impact of treatment that results in a 
sustained effect. This sustained improvement was also seen in scores reflecting urinary 
symptoms and quality of life, reinforcing previous work.1,5,6 
 
A study by Crisp has shown that women with sexual dysfunction, as defined by their FSDS-R 
score, do better if they have a positive coping strategy.12 They define this as implementing a 
response to a stressful situation, either by avoiding the situation, regulating it, or changing the 
emotion attached to the situation. This could partially explain the improvement in sexual 
function noted in our study. Treatment with HA has a positive effect on urinary symptoms 
and the avoidance of recurrent infection as a stressor could be deemed a coping strategy. 
Women will also receive emotional support when attending for bladder instillations, but this 
does not explain the sustained improvement 10 months after treatment was complete.  
 
Renard et al showed that 61.9% women with RUTI exhibited a degree of depression when 
using the Hospital Anxiety and Depression and Leicester scales.13 Being referred for HA 
instillations may decrease concomitant anxiety knowing that a treatment is available. As 
treatment improves urinary symptoms, anxiety may lessen further. Mental and sexual health 
are inextricably linked and a general improvement in affect can improve sexual function.14 
We hypothesise that this general improvement in mood and anxiety may play a part in 
improving sexual function for women with RUTI. A supporting factor for this theory is the 
continued improvement in sexual dysfunction over time. A continued improvement in lower 
urinary tract symptoms will have a gradual improvement in patients’ general mood, affect 
and anxiety. This could explain the more dramatic change between baseline and 12 months 
over baseline and 3 months. A similar effect was shown following endometrial ablation for 
heavy menstrual bleeding in perimenopausal women, where the mean FSDS-R score was 
reduced from 13.6 to 9.7 (p<0.001) before and 6 months after treatment.15 
 
During the planning stages of the study we had not considered the role of mood and 
depression associated with RUTI and it’s impact on sexual dysfunction. We hypothesise this 
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connection but intend to include a depression and anxiety scale to assess patients’ 
psychological health for any future work. We therefore consider this a feasibility and pilot 
study and hope to further our work incorporating this new theory.  
 
We believe that this study is the first to look directly at the effect of intravesical HA 
treatment on sexual dysfunction associated with RUTI. It is powered for statistical 
significance (n>22) and validated questionnaires were used. We acknowledge that there were 
some limitations to the study; there is no specific validated questionnaire for assessing RUTI.  
We therefore utilised the PGI-I scale which has been validated for stress urinary 
incontinence16, prolapse17 and detrusor overactivity18 but we accept that it is not validated for 
use in RUTI.  Further limitations include the limited sample size.  We used a single-arm 
study design and the sample size was small, however it was powered for significance. There 
was a 30% drop out for 12 month follow up data. Long term follow up of patients proved 
very difficult, particularly as many had been discharged following treatment. Some patients 
had moved area and could not be contacted, others did not want to complete the lengthy 
questionnaires again. We appreciate that many of the questions probe into sensitive issues for 
this group of women and repeating the questionnaires four times may be distressing. 
 
The length and number of questionnaires included made the risk of missing data high. Given 
the scoring system for each questionnaire, if a patient missed one component of the question, 
it was not possible to generate an accurate score. As the missing data was sporadic, Little’s 
Test was performed. A significant result of 0.89 proved that data was missing completely at 
random (MCAR) and therefore median calculations for scores could be used. 11 patients did 
not complete 12 month follow up data, but Little’s Test was still significant allowing us to 
perform statistical analysis. 
 
We accept that using two different preparations for intravesical treatment has introduced 
some dis-homogeneity. iAluRil contains two active components, 800mg/50ml Sodium 
Hyaluronate (1.6%) plus 1g/50ml Sodium Chondroitin Sulfate (2%). Cystistat contains only 
Sodium Hyaluronate at a lower concentration of 40mg/50ml. Both preparations were used 
routinely in the Trust and two Consultants were involved with recruitment to the trial and had 
personal preferences for treatment. This was however a pragmatic study, and aimed to look at 
the effect of intravesical treatment for RUTI on associated sexual dysfunction. Previous work 
has shown both preparations to be effect for treating RUTI. 
 
Patients with bacterial and abacterial RUTI were included, and as such many patients never 
had a positive urine dip test, or midstream urine culture.  We therefore did not measure the 
number of confirmed infective episodes experienced by patients, but chose to use a 
symptomatic score questionnaire instead, comparing urinary symptom scores (ICIQ-FLUTS, 
ICIQ-UI) and PGI-I as a marker of improvement. 
 
In conclusion, bladder instillation with HA for RUTI reduce sexual dysfunction associated 
with the condition. This is possibly due to a reduction in pain and lower urinary tract 
symptoms thereby reducing the dysfunction associated with intercourse, or by improving 
patient’s general affect following treatment. The improvement demonstrated is statistically 
significant and was sustained for the 12 month follow up period.  
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Figures and Tables: 
 
 
Table I: Median values of validated questionnaires at baseline, 3, 6 and 12 months. 
 
Median values 
(IR*) 
Baseline 
 
3 months 
 
6 months 
 
12 months 
 
Significance 
(p value) 
FSDS-R 17.00 (37.25) 
4.50 
(22.25) 
7.00 
(23.50) 
1.74 
(19.41) <0.001 
ICIQ-UI 4.00 (6.00) 
1.00 
(4.00) 
1.00 
(5.00) 
1.17 
(3.56) <0.001 
ICIQ-FLUTS 
F 
 
V 
 
I 
 
6.00 
(3.00) 
3.00 
(3.25) 
3.00 
(4.83) 
 
5.00 
(3.01) 
2.00 
(3.20) 
1.00 
(4.00) 
 
3.50 
(3.25) 
2.00 
(2.25) 
1.00 
(3.00) 
 
3.70 
(3.24) 
2.00 
(1.93) 
1.63 
(3.89) 
 
<0.001 
 
0.056 
 
0.035 
ICIQ-VS 
Vaginal 
Symptoms 
Sexual Score 
 
QOL 
 
9.01 
(8.5) 
19.00 
(40.5) 
3.50 
(6.25) 
 
6.00 
(7.25) 
13.00 
(31.03) 
2.33 
(4.66) 
 
4.78 
(4.5) 
11.00 
(30.25) 
1.00 
(3.25) 
 
6.00 
(7.72) 
7.94 
(29.33) 
1.49 
(3.14) 
 
<0.001 
 
0.333 
 
0.017 
 
O’Leary/Sant 
Symptoms 
 
Problems 
 
9.21 
(5.25) 
7.97 
(7.25) 
 
6.00 
(3.00) 
4.00 
(6.00) 
 
6.00 
(5.25) 
3.00 
(5.25) 
 
8.36 
(5.81) 
4.00 
(4.32) 
 
<0.001 
 
<0.001 
PGI-I N/A  
5.73 
(1.25) 
6.00 
(1.21) 
6.25 
(1.82) 0.001 
 
* Interquartile range 
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Graph I: Showing improvement in ICIQ-VS Sexual Matters and FSDS-R scores over the 
course of follow up. 
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